Solara Active Pharma Sciences has allotted 1500 equity shares under ESOP on 17 December 2025. With this allotment, the equity share capital has increased to 3,61,72,807 fully paid up equity shares. Powered by Capital Market - Live News

Solara Active Pharma Sciences has appointed Mohanraj S(DIN: 08420411) as an Additional - Executive Director and Whole -Time Director for a period of 3 years with effect from 01 January 2026 subject to approval of the Shareholders of the Company.Powered by Capital Market - Live News

Solara Active Pharma Sciences announced that its multi-product manufacturing facility at Mangalore, Karnataka has successfully completed the inspection carried out by the US Food and Drug Administration (US FDA) between 25 to 29 August 2025. The Agency has issued an EIR (Establishment Inspection Report) on 18th Nov 2025 and determined that the inspection classification of the facility is �Voluntary Action Indicated (VAI)� and concluded this inspection as closed.Powered by Capital Market - Live News

Net loss of Solara Active Pharma Sciences reported to Rs 10.10 crore in the quarter ended September 2025 as against net profit of Rs 8.01 crore during the previous quarter ended September 2024. Sales declined 9.63% to Rs 313.54 crore in the quarter ended September 2025 as against Rs 346.95 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales313.54346.95 -10 OPM %11.0817.67 - PBDT14.3933.35 -57 PBT-10.108.01 PL NP-10.108.01 PL Powered by Capital Market - Live News

Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live News